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Background: Lower respiratory tract infections are a leading cause of death in young children, but few studies have collected the 
specimens needed to define the role of specific causes. The Child Health and Mortality Prevention Surveillance (CHAMPS) platform 
aims to investigate causes of death in children aged <5 years in high–mortality rate settings, using postmortem minimally invasive 
tissue sampling and other advanced diagnostic techniques. We examined findings for deaths identified in CHAMPS sites in 7 coun-
tries in sub-Saharan Africa and south Asia to evaluate the role of respiratory syncytial virus (RSV).
Methods: We included deaths that occurred between December 2016 and December 2019. Panels determined causes of deaths 
by reviewing all available data including pathological results from minimally invasive tissue sampling, polymerase chain reaction 
screening for multiple infectious pathogens in lung tissue, nasopharyngeal swab, blood, and cerebrospinal fluid samples, clinical in-
formation from medical records, and verbal autopsies.
Results: We evaluated 1213 deaths, including 695 in neonates (aged <28 days), 283 in infants (28 days to <12 months), and 235 
in children (12–59 months). RSV was detected in postmortem specimens in 67 of 1213 deaths (5.5%); in 24 deaths (2.0% of total), 
RSV was determined to be a cause of death, and it contributed to 5 other deaths. Younger infants (28 days to <6 months of age) ac-
counted for half of all deaths attributed to RSV; 6.5% of all deaths in younger infants were attributed to RSV. RSV was the underlying 
and only cause in 4 deaths; the remainder (n = 20) had a median of 2 (range, 1–5) other conditions in the causal chain. Birth defects 
(n = 8) and infections with other pathogens (n = 17) were common comorbid conditions.
Conclusions: RSV is an important cause of child deaths, particularly in young infants. These findings add to the substantial body 
of literature calling for better treatment and prevention options for RSV in high–mortality rate settings.
Keywords:  Respiratory syncytial virus; child mortality; cause of death.
Infections of the lower respiratory tract, such as pneumonia 
and bronchiolitis, are a leading cause of serious illness and 
death among children <5 years of age, with a disproportionate 
burden occurring in low- and middle-income settings [1]. 
Developing targeted treatment and prevention measures relies 
on understanding the burden and etiology of these infections. 
Studying etiology is difficult, however, because obtaining sam-
ples directly from the site of disease—inside the lung—is rarely 
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possible. Studies of pneumonia etiology have relied primarily 
on tests of specimens from other sites, such as swab specimens 
of the upper respiratory tract or blood cultures, or specimens 
such as sputum that may contain oral flora, all of which pose 
significant limitations as proxies of what is really occurring in 
the lung; a limited number have included pleural fluid or lung 
aspirates.
Respiratory syncytial virus (RSV) is a common cause of 
lower respiratory tract infections (LRTIs), resulting in an es-
timated 3.2 million hospitalizations globally each year, with 
approximately 60  000 in-hospital deaths; just under half are 
among children <6 months of age [2]. The number of overall 
RSV-associated deaths may range between 55 000 and 200 000 
annually [3]. However, meta-analytic estimates are limited by 
diagnostic assay variability and inconsistent case definitions 
among other considerations. Very limited primary data are 
available from which more precise, accurate estimates can be 
made [4].
The Pneumonia Etiology for Child Health (PERCH) study 
used a case-control design and mathematical modeling to de-
termine the causes of LRTIs based on testing of blood samples, 
nasopharyngeal and oropharyngeal swab samples, induced 
sputum samples, and, in a small subset of cases, lung aspirates 
and pleural fluid samples. PERCH estimated that RSV accounted 
for 31% of chest radiography–confirmed pneumonia overall in 
children aged 1 to 59 months, with a range of 21%–36% among 
their different study sites in Sub-Saharan Africa and Asia, and 
suggested that detecting RSV in the upper respiratory tract of 
patients (when patients with lower respiratory tract infection 
were compared with controls) was highly associated with illness 
[5]. Similarly, RSV was found to be the leading pathogen in the 
Aetiology of Neonatal Infections in South Asia (ANISA) study 
[6]. In the Etiology of Pneumonia In the Community (EPIC) 
study, RSV was detected in 37% of pneumonia hospitalizations 
among children <5 years old in the United States, using similar 
diagnostic measures as the PERCH study [7].
Child and Mortality Prevention Surveillance (CHAMPS) was 
established to determine the causes of deaths among stillbirths, 
newborns, infants, and children <5 years of age in high–mor-
tality rate settings. CHAMPS goes beyond previous work on 
pneumonia etiology by not only obtaining blood and upper res-
piratory tract samples, but also collecting multiple postmortem 
tissue samples from the lungs and other organs and examining 
them by polymerase chain reaction (PCR) and pathology tech-
niques. These results, along with data from clinical records and 
verbal autopsy, are reviewed by trained multidisciplinary panels 
to attribute causes of death.
In this article, we focus on the role of RSV as a cause of child 
deaths. We describe how often RSV is identified among cases 
enrolled in CHAMPS and the characteristics of children who 
died of RSV. We examine circumstances when comorbidities 
along with RSV resulted in death and cases in which RSV was 
detected but not determined to be in the chain of events leading 
to death.
METHODS
The analysis included deaths enrolled in CHAMPS sites be-
tween December 2016 and December 2019. CHAMPS protocol 
and methods are described elsewhere (www.champshealth.org) 
[8, 9]. Briefly, enrollment occurred in 10 sites in 7 countries in 
Asia and Africa: Baliakandi and Faridpur, Bangladesh; Harar 
and Kersa, Ethiopia; Siaya and Kisumu, Kenya; Bamako, Mali; 
Manhiça, Mozambique; Bombali, Sierra Leone; and Soweto, 
South Africa [10]. The CHAMPS site in Mozambique began 
enrollment in 2016, sites in South Africa, Kenya, Mali, and 
Bangladesh began in 2017, and Sierra Leone and Ethiopia began 
in 2019.
Children who were <5 years of age at the time of death and 
were residents of a catchment area were eligible for enrollment. 
Parents or guardians were approached for consent for verbal au-
topsy and clinical chart abstraction; permission was also sought 
for specimen collection and testing for children whose deaths 
were identified within 24 hours of occurrence. Only deaths 
occurring in children who were born alive and for whom com-
plete specimen collection and testing were performed are in-
cluded in this analysis. We did not include stillbirths because 
none enrolled in CHAMPS during this time period tested 
positive for RSV. Ethics committees at each site and at Emory 
University, Atlanta, Georgia, approved overall protocol and site 
ethics committees approved site specific protocols, respectively. 
The US Centers for Disease Control and Prevention committee 
deferred to the Emory University review.
CHAMPS pathology teams collected minimally invasive 
tissue samples [11] from enrolled subjects as well as periph-
eral blood, cerebrospinal fluid, stool or rectal swab, and naso-
pharyngeal swab samples. Site laboratories tested postmortem 
blood samples for human immunodeficiency virus DNA or 
RNA using PCR and for malaria using thick and thin smears 
and rapid diagnostic assays; blood and cerebrospinal fluid sam-
ples underwent microbial culture for bacterial pathogens. Real-
time reverse-transcription PCR for detection of 116 pathogens 
was performed at each site using 4 custom-designed syndromic 
TaqMan array cards (TACs; Thermo Fisher Scientific) [12]; lung 
tissue and nasopharyngeal swab samples were tested for RSV 
and other respiratory pathogens, blood and cerebrospinal fluid 
samples for pathogens causing sepsis and meningitis, and stool 
samples for enteric pathogens. TAC testing targeted the RSV 
matrix (M) protein gene [12].
Tissue specimens were examined locally using routine histo-
pathological techniques, and, if indicated by tissue appearance 
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or TAC results, special staining techniques targeting micro-
organisms and immunohistochemistry were performed at the 
Infectious Diseases Pathology Branch of the Centers for Disease 
Control and Prevention [13]. Immunohistochemistry testing 
for RSV was performed on lung tissue using goat polyclonal an-
tiserum raised against RSV.
Determination of cause of death (DeCoDe) panels con-
vened at each site and reviewed information for each death 
once data collection and specimen testing were complete. The 
data reviewed included all postmortem diagnostics, clinical 
abstraction from child and maternal health records and verbal 
autopsy responses. DeCoDe panels consisted of ≥5 local ex-
perts, such as pediatricians, pathologists, obstetricians, nurses 
or other healthcare providers, epidemiologists, and microbiol-
ogists, with support from the CHAMPS Program Office [14]. 
Panels determined the chain of events leading to death using 
the World Health Organization (WHO) International Statistical 
Classification of Diseases and Related Health Problems, Tenth 
Revision (ICD-10) and WHO application of ICD-10 for peri-
natal deaths (ICD-PM) guidelines [15,16]. 
For deaths in children attributed to a single condition, that 
condition was considered the underlying cause of death. For 
deaths in which >1 condition played a role, underlying, interme-
diate (also known as comorbid or antecedent), and immediate 
causes were assigned. We defined the causal chain or pathway 
to include all conditions listed as underlying, intermediate and 
immediate causes of death. Other factors that may have contrib-
uted but were deemed to not directly cause the death were listed 
as contributing (part 2 in the standard ICD-10 death certificate) 
but not considered in the causal chain. To ensure consistency 
across DeCoDe panels, the network used diagnosis standards 
for defining common childhood causes of death, panel mem-
bers underwent training, and a subset of cases were exchanged 
between sites for review. Panel members attributed deaths to 
pneumonia and/or RSV along with the certainty of that diag-
nosis based on predefined standards (Supplementary Table 1).
DeCoDe panels considered whether RSV belonged in the 
causal pathway of death, taking into account the role of concur-
rent medical conditions. Therefore, cases from which RSV was 
detected do not necessarily have RSV in the causal pathway. In 
addition to assigning conditions to the causal chain leading to 
death, DeCoDe panel members also considered whether appro-
priate management or prevention efforts could have prevented 
the death.
Statistical Analysis
Data analyses examined features of deaths that were or were not 
attributed to RSV according to DeCoDe panel evaluations. Case 
studies were included to provide illustrative examples. Any 
death with RSV noted as an underlying, intermediate, or im-
mediate cause was defined as an RSV death. LRTI deaths were 
defined as deaths in which pneumonia or viral pneumonitis 
was listed in the causal chain. We evaluated the data using de-
scriptive analyses, such as frequency distributions, for 2 groups: 
(1) deaths in which RSV was determined to be in the causal 
chain by DeCoDe panel review and (2) deaths in which RSV 
was detected by PCR but for which DeCoDe panels determined 
that RSV did not cause the death. We conducted χ 2 analysis 
to compare differences between RSV deaths and deaths from 
other causes for factors such as age group (neonate, from birth 
to <28  days; infant, 28  days to <12  months; and child ,12 to 
<60  months), CHAMPS site, and other conditions present at 
death. Differences were considered statistically significant at P 
< .05. Analyses were conducted using SAS (version 9.4).
RESULTS
Between December 2016 and December 2019, CHAMPS sites 
enrolled and determined causes for 1213 deaths in live-born 
children <5  years of age, including 695 (57%) deaths in neo-
nates, 283 (23%) in infants, and 235 (19%) in children (Table 
1). Among these deaths, RSV was detected in postmortem spe-
cimens in 67 (5.5% of all deaths), and it was determined to be a 
cause of death in 24 (2.0% of all deaths; Figure 1). RSV was the 
only or underlying cause for 4 (17%) deaths due to RSV and an 
immediate or antecedent cause for 20 (83%). RSV was deter-
mined to be a contributing rather than causal condition for 5 
additional deaths. One death attributed to RSV as the under-
lying cause had RSV detected by premortem clinical testing. 
This death occurred in a 4-month-old infant who required 
intensive care for RSV bronchiolitis, was discharged and re-
admitted a week later with respiratory distress, and then died; 
the immediate cause of death was determined to be adenovirus 
pneumonia, and results of postmortem testing for RSV were 
negative.
Most deaths with RSV detected were identified in the South 
Africa CHAMPS site (29 of 67 [43.3%]), which represents a 
similar proportion of total deaths enrolled in CHAMPS during 
this time (497 of 1213 [41.0%]). Proportionally, RSV was de-
tected most frequently in cases from Ethiopia (3 of 28 [10.7%]) 
and Mali (10 of 103 [9.7%]) and listed in the causal chain most 
frequently in the same countries (3.6% and 3.9%, respectively 
(Figure 2 and Supplementary Table 2). RSV was rarely detected 
among deaths occurring within the first week of life (7 of 558 
[1.3%]); none of the deaths in this age group were attributed 
to RSV or determined to have RSV as a contributing condi-
tion (Figure 2). RSV was detected among 11.7% (33 of 283) of 
deaths in infants (aged 28 days to <12 months) and in 8.9% (21 
of 235) of children. 
Younger infants (aged 28  days to <6  months of age) ac-
counted for half of all deaths attributed to RSV (12 of 24 
[50%]), and RSV was determined to have caused 6.5% of all 
deaths in this age group. Among all cases with RSV detected, 
younger infants more commonly had RSV determined to be a 
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cause of death when detected (12 of 22 [54.5%]) compared with 
older infants and children (9 of 32 [28.1%]; P = .05). Infants 
<4  months of age, the age group most likely to be protected 
by maternal RSV immunization, accounted for 8 of 24 deaths 
caused by RSV (33%) and 18 of 67 RSV detections (27%). 
Deaths with RSV detection occurring during the typical respi-
ratory season at each site were more often attributed to RSV (19 
of 602 [3.2%]) than deaths in other seasons (5 of 611 [0.8%]; 
P = .003). Similarly, RSV was detected more often during the 
respiratory season for each site (52 of 602 [8.3%]) than during 
other seasons (15 of 611 [2.5%]; P < .001). Although this dif-
ference was not significant, a higher proportion of community 
deaths (those occurring outside a health facility) had RSV de-
tected, when compared with the deaths within a health facility 
(8.3% vs 4.9%, respectively).
All deaths with lung tissue that tested positive by 
immunohistochemistry for RSV (10 of 19 tested with 
immunohistochemistry) had RSV in the causal chain. Likewise, 
RSV was determined to be in the causal chain more often for 
deaths in which RSV was detected by PCR in postmortem 
samples from both the nasopharynx and lungs (17 of 22 [77.3%]; 
Table 2), compared with deaths in which RSV was detected in 
only 1 specimen type (4 of 31 [12.9%] with only the nasopha-
ryngeal swab sample positive and 2 of 14 [14.3%] with only lung 
tissue positive; both P < .001). None of the deaths within the 
first 7 days of life had RSV detected by PCR in both specimen 
types (Table 2).
Among the 24 deaths in which RSV was in the causal chain, 
RSV was determined to be the underlying and only cause of 
death for 4 cases (16.7%; example in Figure 3B). Among those 
with other conditions, the median number of other conditions 
in the causal chain was 2 (range, 1–5; Figure 4A). The number 
of other conditions in the causal chain did not differ between 
deaths before 6  months of age and deaths among older chil-
dren (both with a median of 2 other conditions) or between 
whose deaths occurring in the community and those occurring 
in health facilities (both median 2 other conditions). Birth de-
fects were common among deaths attributed to RSV, being 
listed in the causal chain for 8 (33.3%) deaths (Supplementary 
Table 3). Seventeen of 24 RSV-associated deaths (70.8%) had 
Table 1. Characteristics of Neonatal, Infant, and Child Deaths Enrolled in Child Health and Mortality Prevention Surveillance (CHAMPS), for all Deaths 
Reviewed by Determination of Cause of Death Panels, Deaths Those With Respiratory Syncytial Virus (RSV) Detected at Postmortem Testing, and Deaths 
With RSV in the Causal Chain
Characteristic
Deaths, No. (%)a
All Deaths (N = 1213) Deaths With RSV Detected (n = 67)
Deaths With RSV in 
Causal Chain (n = 24)
Age at death
 <24 h 289 (24) 5 (7.5) 0 (0)
 Early neonate (24 h to 6 d) 269 (22) 2 (3.0) 0 (0)
 Late neonate (7 to 27 d) 137 (11) 6 (9.0) 3 (12)
 Infant (28 d to <6 mo) 184 (15) 22 (33) 12 (50)
 Infant (6 to <12 mo) 99 (8.0) 11 (16) 3 (12)
 Child (12 to <60 mo) 235 (19) 21 (31) 6 (25)
Age at death, mean (median), d 200 (10) 339 (166) 276 (139)
Male sex 677 (56) 32 (48) 10 (42)
Location of death    
 Communityb 194 (16) 16 (24) 5 (21)
 Health facility 1019 (84) 51 (76) 19 (79)
Season of death    
 Peak respiratory seasonc 602 (50) 52 (78) 19 (79)
 Not respiratory season 611 (50) 15 (22) 5 (21)
Time between death and MITS procedure, median (range), h 15 (0–97) 16 (0–63) 19 (5–47)
CHAMPS site    
 Bangladesh 80 (7) 2 (3.0) 0 (0)
 Ethiopia 28 (2) 3 (4.5) 1 (4.2)
 Kenya 281 (23) 18 (27) 4 (17)
 Mali 103 (8) 10 (15) 4 (17)
 Mozambique 125 (10) 3 (4.5) 0 (0)
 Sierra Leone 99 (8) 2 (3.0) 0 (0)
 South Africa 497 (41) 29 (43) 15 (63)
Abbreviations: CHAMPS, Child Health and Mortality Prevention Surveillance; MITS, minimally invasive tissue sampling; RSV, respiratory syncytial virus.
aData represent no. (%) of deaths unless otherwise specified.
bCommunity deaths include those that occurred at home or on the way to a health facility.
cRespiratory season was defined as follows for the surveillance sites: Bangladesh, June–September; Ethiopia, April–May and October–November; Kenya, May–September; Mali, July–
September; Mozambique, January–July; Sierra Leone, September–January; and South Africa, February–September.
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LRTIs attributed to another pathogen in the causal pathway in 
addition to RSV; Klebsiella pneumoniae (n = 9), Haemophilus 
influenzae (n = 4), and rhinovirus (n = 3) were most common 
among the other pathogens identified in these deaths (Figure 5).
DeCoDe panels determined that other infectious causes 
caused death in the majority (27 of 39 [69.2%]) of deaths in 
children <5  years of age with RSV detected in postmortem 
specimens but for which RSV was not a causal or contributing 
Figure 1. Flowchart of enrollment of deaths among children <5 years of age in Child Health and Mortality Prevention Surveillance (CHAMPS) sites, detection of respiratory 
syncytial virus (RSV) among deaths with minimally invasive tissue samples (MITS) tested for RSV, and identification of deaths determined by review panels (determination of 
cause of death [DeCoDe] panels) to be caused by RSV or other conditions.
Figure 2. Proportion of deaths with respiratory syncytial virus (RSV) detected and with RSV determined to be in the causal chain leading to death, by Child Health and 
Mortality Prevention Surveillance (CHAMPS) site.
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condition (Figure 6; examples in Figures 3B and 3C). The me-
dian number of conditions in the causal chain in this group 
was 2 (range, 1–6; Figure 4B); 21 of 39 deaths (54%) did not 
have an LRTI of any type among the conditions listed. Among 
7 deaths that occurred in the first week of life with RSV de-
tected, 1 was attributed to another infection (pneumonia due 
to K.  pneumoniae), and 6 were determined to be caused by 
noninfectious causes, including complications of preterm birth 
(n = 2), birth defects (n = 2), hypoxic ischemic encephalopathy 
(n = 1), and perinatal asphyxia (n = 1).
DISCUSSION
Our results confirm that RSV is an important cause of death 
in children <5 years old, especially among infants 28 days to 
<6 months of age; in this age group, 1 of every 15 deaths was 
caused by RSV. Half of the deaths identified and attributed to 
RSV were in these younger infants, as were cases in which RSV 
was thought to have contributed to, but not caused, the death. 
The findings on age distribution and seasonality for RSV are 
consistent with previous work describing RSV burden and ep-
idemiology [17].
DeCoDe panelists more often attributed a death to RSV 
when immunohistochemical staining identified RSV in 
lung tissue or when PCR demonstrated RSV in both lung 
tissue and nasopharyngeal specimens. Just under half of the 
deaths in which RSV was detected were attributed to RSV by 
CHAMPS DeCoDe panels. About 1 in 4 deaths with RSV de-
tected that were ultimately not determined to be RSV deaths 
were not attributed to any infectious cause, suggesting that 
RSV may have been present but not causing serious symp-
toms in these children. Our findings differ from studies of 
RSV prevalence among healthy children. In the multicountry 
PERCH study, only about 4% of control children <5  years 
of age in the community had RSV detected in upper airway 
samples [5], and in the US EPIC study, <3% of asymptomatic 
control children had RSV detected [7]. While CHAMPS 
methods include careful evaluation of lung tissue with sen-
sitive techniques, such testing can miss part of the sequence 
of events leading to death, and some deaths not attributed to 
RSV based on postmortem findings may have been attrib-
uted to RSV if diagnostic test results had been available from 
earlier in the illness course. For example, the Staphylococcus 
aureus pneumonia death described in Figure 3B may have 
been the result of an earlier RSV infection in which the virus 
was no longer detectable in the lung at time of death, but the 
DeCoDe panel could not make such a determination from 
the available evidence.
RSV causes many serious infections in healthy infants and 
young children. A large majority of the deaths we identified and 
attributed to RSV, however, were in children who had other con-
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Figure 3. A. Findings in a newborn with respiratory syncytial virus (RSV) determined to be the underlying and only cause of death. The subject was a 22-day-old girl, born 
in a healthcare facility at 38 weeks’ gestation (birthweight, 3400 g) to a mother who was positive for human immunodeficiency virus (HIV) and receiving treatment. The new-
born was seen at a referral hospital after a week of difficulty breathing; the father refused admission, and the newborn was discharged on antibiotics. She developed a fever, 
was seen in the clinic, and was again referred for hospital care. She died at home that night. Postmortem testing was negative for HIV, tuberculosis, and malaria; blood and 
cerebrospinal fluid cultures were also negative. Polymerase chain reaction (PCR) testing identified RSV in lung tissue and a nasopharyngeal (NP) specimen; the latter also 
contained Klebsiella pneumoniae, Staphylococcus aureus, Moraxella catarrhalis, Haemophilus influenzae, and rhinovirus. Pathology found mild steatosis and extramedullary 
hematopoiesis in the liver, and interstitial pneumonitis in specimens from both lungs. Both images show lung tissue; the arrows in left image indicate multinucleated syn-
cytial cells, and the circle in right image, positive immunohistochemical (IHC) staining in these cells. B, Findings after death caused by a chronic infected ulcer (underlying 
cause), with subsequent pneumonia caused by S. aureus and Streptococcus pneumoniae (morbid causes) and S. aureus sepsis (immediate cause) in a malnourished infant 
(part 2 contributing cause); RSV was detected but not deemed a cause of death. This subject was a 6-month-old girl born at 36 weeks’ gestation (birthweight, 3165 g). She 
RSV Role in Deaths Among Children <5 Years Old • cid 2021:73 (Suppl 3) • S225
that RSV deaths mostly occur among children who are especially 
vulnerable, such as those with a birth defect or concurrent bacterial 
infections or whose RSV leads to other subsequent infections with 
other pathogens. The number of different pathogens identified and 
determined to be in the causal chain highlights the fact that severe 
pneumonia episodes may often be caused by >1 pathogen. In addi-
tion, our results demonstrate the hazard of attributing causality to 
antemortem diagnostic testing results, in particular those from the 
upper respiratory tract, or to microbiological results in the absence 
of histopathological evidence.
Applying histopathology to investigations of cause of death 
allows a substantial capacity to discern causes of severe illnesses 
leading to death that is much more specific and robust than 
methods more routinely used in high–mortality rate settings, such 
Figure 4. A. Number of conditions in the causal chain for deaths attributed to respiratory syncytial virus (RSV) (n = 24), by age group. B, Deaths in which RSV was detected 
but not determined to be in the causal pathway (n = 43).
presented with 1 day of cough, fever, lethargy, and decreased milk intake and 2 days of diarrhea. She had been receiving oral and topical medications for an occipital ulcer. 
At the admission examination, she was hot to the touch, hydrated, and in respiratory distress, with grunting, alar flaring, a respiratory rate of 62/min, and a pulse rate of 178 
/min. She was treated with gentamicin and ampicillin but died the following day. S. aureus grew in cultures collected before death from the occipital abscess and blood. 
The infant’s weight and height at postmortem examination were 6.07 kg and 60 cm, respectively (weight-for-age z score, −2.18; weight-for-height z score, −1.5). Results of 
postmortem tests for HIV, tuberculosis, and malaria were negative. S. aureus grew in lung tissue culture. PCR testing detected S. aureus in blood and lung tissue. Lung tissue 
was also positive for S. pneumoniae. PCR results in an NP swab specimen were positive for RSV, H. influenzae, M. catarrhalis, S. pneumoniae, and S. aureus; a stool sample 
was positive for adenovirus 40/41 and Escherichia coli. Liver tissue pathology showed severe large- and small-droplet steatosis. Right and left lung specimens showed severe 
necrotizing bronchopneumonia (left image), with IHC staining positive for S. aureus (not shown) and S pneumoniae (red staining in right image). C, Findings after death in a 
child caused by HIV with wasting syndrome (underlying cause), malaria (morbid condition), and E. coli sepsis (immediate cause); severe anemia and polymicrobial pneumonia 
due to RSV, E. coli, and S. pneumoniae were considered contributing (part 2) causes. The child was a 21-month-old girl admitted to the hospital with a history of cough, 
fever, vomiting, and rash localized at her mouth, elbows, and buttocks. On examination, she appeared ill and wasted and was febrile. Antemortem diagnoses included severe 
anemia, severe malaria, pneumonia, and malnutrition; she died on hospital day 11. Postmortem weight and height were 6.7 kg and 82.1 cm, respectively (weight-for-age z 
score, −4.04; weight-for-height z score, −5.1). At postmortem examination, she appeared malnourished and pale, with healed sacral and trochanteric pressure sores and right 
elbow sores. HIV testing results were positive; results of testing for tuberculosis and malaria were negative, and a blood culture grew E. coli. PCR testing of blood identified 
E. coli and Plasmodium falciparum; lung tissues were positive for RSV, cytomegalovirus, M. catarrhalis, S. pneumoniae, Pneumocystis jirovecii, and K. pneumoniae; an NP 
specimen was positive for RSV, K. pneumoniae, S. pneumoniae, S. aureus, M. catarrhalis, Pseudomonas aeruginosa, and cytomegalovirus; and a stool sample was positive 
for E. coli, and Enterovirus. At pathological examination of the liver, extensive large- and small-droplet steatosis and sinusoidal leukocytosis were noted, and results of IHC 
testing were positive for malaria; bacterial bronchopneumonia and focal interstitial pneumonitis were seen in lung tissue. IHC tests in lung tissuee detected E. coli (left image) 
and S. pneumoniae (right image).
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as verbal autopsy [18]. Nonetheless, our study has important lim-
itations. First, CHAMPS is relatively new in some sites, meaning 
that a longer duration of surveillance might detect years in which 
RSV is more prevalent than observed to date. Next, RSV could 
cause infections that lead to fatal complications, but the pathogen 
may be undetectable in postmortem samples at the time of death, 
especially if the death occurred many days or even weeks after 
illness onset. In addition, in deaths that occur in children with 
complicated medical courses, discerning the role of RSV among 
many possible causes can be difficult. Finally, the number of RSV-
associated deaths occurring in the community may be under-
appreciated by the results presented here, as thus far CHAMPS 
more often enrolls deaths that occur in health facilities. Taken 
together, these challenges suggest that the proportion of deaths 
in infants and children attributed to RSV in this analysis should 
be considered a minimal estimate of the true burden. Linking 
CHAMPS data to other data on RSV infections is needed to better 
quantify the burden of RSV and its role in deaths.
Figure 6. Causes of death determined by Child Health and Mortality Prevention Surveillance (CHAMPS) review (determination of cause of death) panels for the 67 deaths with specimens 
that tested positive for respiratory syncytial virus (RSV), by age group. Results are grouped by whether (1) RSV was in the causal chain of events leading to death (blue); (2) RSV contributed, 
but other conditions caused the death (orange); (3) infections other than RSV caused the death (gray); or (4) the death was caused by conditions that were not infectious.
Figure 5. Other pathogens determined to be in the causal chain leading to death. Abbreviations: CMV, cytomegalovirus; E coli, Eschericia coli; GBS, Group B streptococcus; 
hMPV, human metapneumovirus.
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Our findings join the substantial body of literature calling for 
better treatment and prevention measures for RSV, in particular 
for high–mortality rate settings. While review of the treatments 
received by the children in our study was beyond the scope of 
this analysis, improving the availability of oxygen and other 
types of supportive care in hospitals in low- and middle-income 
countries would likely improve outcome for many patients with 
RSV. It is a WHO priority to develop RSV monoclonal anti-
bodies and vaccines that could be given to infants or vaccines 
that mothers would receive during pregnancy [19], and a recent 
review identified dozens of products in development or clinical 
trials [20, 21].
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